Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Nivolumab

5

XII.d Myocarditis (can be fulminant)

1
Last update : 23/07/2016
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Avelumab
1
Durvalumab
3
Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx
5
Lambrolizumab
4
PD-1/PD-L1-inhibitors or blocking agents/drugs
5
Pembrolizumab
5

Publications

Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis.
Investigational new drugs 2024 Feb;42;116-126 2024 Feb
Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
Internal medicine journal 2020 Aug;50;1003-1006 2020 Aug
Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab.
Journal of forensic sciences 2018 May;63;954-957 2018 May
Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
The Canadian journal of cardiology 2018 Jun;34;812.e1-812.e3 2018 Jun
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
Neurology 2017 Sep 12;89;1127-1134 2017 Sep 12
Smoldering myocarditis following immune checkpoint blockade.
Journal for immunotherapy of cancer 2017 Nov 21;5;91 2017 Nov 21
Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.
Lung cancer (Amsterdam, Netherlands) 2016 Sep;99;117-9 2016 Sep
Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.
BMJ case reports 2016 Jul 20;2016; 2016 Jul 20

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies